Unknown

Dataset Information

0

Synthetic Cannabinoids Induce Autophagy and Mitochondrial Apoptotic Pathways in Human Glioblastoma Cells Independently of Deficiency in TP53 or PTEN Tumor Suppressors.


ABSTRACT: Glioblastomas (GBMs) are aggressive brain tumors with frequent genetic alterations in TP53 and PTEN tumor suppressor genes rendering resistance to standard chemotherapeutics. Cannabinoid type 1 and 2 (CB1/CB2) receptor expression in GBMs and antitumor activity of cannabinoids in glioma cells and animal models, raised promises for a targeted treatment of these tumors. The susceptibility of human glioma cells to CB2-agonists and their mechanism of action are not fully elucidated. We determined CB1 and CB2 expression in 14 low-grade and 21 high-grade tumor biopsies, GBM-derived primary cultures and established cell lines. The non-selective CB receptor agonist WIN55,212-2 (but not its inactive enantiomer) or the CB2-selective agonist JWH133 induced apoptosis in patient-derived glioma cultures and five established glioma cell lines despite p53 and/or PTEN deficiency. Growth inhibitory efficacy of cannabinoids correlated with CB1/CB2 expression (EC50 WIN55,212-2: 7.36-15.70 µM, JWH133: 12.15-143.20 µM). Treatment with WIN55,212-2 or JWH133 led to activation of the apoptotic mitochondrial pathway and DNA fragmentation. Synthetic cannabinoid action was associated with the induction of autophagy and knockdown of autophagy genes augmented cannabinoid-induced apoptotic cell death. The high susceptibility of human glioblastoma cells to synthetic cannabinoids, despite genetic defects contributing to apoptosis resistance, makes cannabinoids promising anti-glioma therapeutics.

SUBMITTER: Ellert-Miklaszewska A 

PROVIDER: S-EPMC7865605 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Synthetic Cannabinoids Induce Autophagy and Mitochondrial Apoptotic Pathways in Human Glioblastoma Cells Independently of Deficiency in <i>TP53</i> or <i>PTEN</i> Tumor Suppressors.

Ellert-Miklaszewska Aleksandra A   Ciechomska Iwona Anna IA   Kaminska Bozena B  

Cancers 20210122 3


Glioblastomas (GBMs) are aggressive brain tumors with frequent genetic alterations in <i>TP53</i> and <i>PTEN</i> tumor suppressor genes rendering resistance to standard chemotherapeutics. Cannabinoid type 1 and 2 (CB1/CB2) receptor expression in GBMs and antitumor activity of cannabinoids in glioma cells and animal models, raised promises for a targeted treatment of these tumors. The susceptibility of human glioma cells to CB2-agonists and their mechanism of action are not fully elucidated. We  ...[more]

Similar Datasets

| S-EPMC8732281 | biostudies-literature
| S-EPMC3698539 | biostudies-literature
| S-EPMC9552912 | biostudies-literature
| S-EPMC4253059 | biostudies-literature
| S-EPMC3022633 | biostudies-literature
| S-EPMC10795032 | biostudies-literature
| S-EPMC2386290 | biostudies-literature
| S-EPMC5556362 | biostudies-other
| S-EPMC7211175 | biostudies-literature
| S-EPMC9126970 | biostudies-literature